Related Experiment Video
Updated: May 16, 2025

Clinical Application of Single-Surgeon, Three-Port, Laparoscopic Resection for Colorectal Cancer with Natural Orifice Specimen Extraction
Published on: March 24, 2023
Reduction in surgical interventions in melanoma.
Alexander C J van Akkooi1, Alexander M M Eggermont2
1Melanoma Institute Australia, Sydney, NSW, Australia; Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia; Department of Melanoma and Surgical Oncology, Institute of Academic Surgery, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Melanoma treatment is shifting away from extensive surgeries like sentinel lymph node biopsy (SLNB). New biomarkers and less invasive methods are making SLNB largely redundant for many melanoma patients.
Area of Science:
- Oncology
- Surgical Oncology
- Dermatology
Background:
- Melanoma surgical practices have evolved, reducing excision margins and questioning the necessity of elective lymph node dissection (ELND) and sentinel lymph node biopsy (SLNB).
- Recent data indicate a low frequency of residual tumor cells in wide local excision (WLE) specimens, especially for less advanced melanomas (pT2 or lower).
- Completely excised primary melanomas show comparable clinical outcomes to those treated with WLE.
Purpose of the Study:
- To evaluate the evolving role of surgical interventions in melanoma management.
- To assess the impact of novel biomarkers and treatment strategies on the necessity of SLNB and other surgical procedures.
- To project future trends in melanoma treatment, focusing on reducing surgical burden.
Main Methods:
- Review of recent studies on melanoma surgical margins, WLE specimen analysis, and clinical outcomes.
- Analysis of the utility of clinicopathological gene expression profilers (CP-GEP) in risk stratification and therapy decisions.
- Evaluation of the benefits of adjuvant and neoadjuvant therapies in different melanoma stages, particularly stage III and IIB/C.
Main Results:
- Wide local excision (WLE) margins have decreased to 1-2 cm, with 97% of patients with pT2 or lower tumors not benefiting from it.
- Clinicopathological gene expression profilers (CP-GEP) can effectively stratify melanoma risk, potentially making SLNB redundant for clinical stage I/II.
- SLNB shows a lack of clear overall survival benefit for adjuvant therapy in stage III and is redundant for anti-PD1 therapy decisions in stage IIB/C.
Conclusions:
- Sentinel lymph node biopsy (SLNB) may soon become obsolete, replaced by standard CP-GEP testing for clinical management.
- Future melanoma treatment will likely involve a significant reduction in surgical interventions.
- CP-GEP testing offers a pathway to simplify follow-up schedules for low-risk patients and reduce overall surgical burden.
More Related Videos
09:38Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity
Published on: January 31, 2025
13:35Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction
Published on: May 17, 2024